FindTrial
Sign In

Hiltonol

DRUG5 trials

Sponsors

Oncovir, Inc., Massachusetts General Hospital, Gliknik Inc., Mustafa Khasraw, MBChB, MD, FRCP, FRACP

Conditions

Breast CancerGlioma, MalignantHead and Neck CancerMelanomaNon-Melanoma Skin CancersSarcomaSmoldering Multiple MyelomaSquamous Cell Carcinoma of the Oral Cavity

Phase 1

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Active, not recruitingNCT02826434
Massachusetts General HospitalBreast Cancer
Start: 2016-08-18End: 2027-09-30Target: 22Updated: 2025-10-01
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Active, not recruitingNCT02886065
Massachusetts General HospitalSmoldering Multiple Myeloma
Start: 2017-03-07End: 2026-09-15Updated: 2026-03-13
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Active, not recruitingNCT05283109
Mustafa Khasraw, MBChB, MD, FRCP, FRACPGlioma, Malignant
Start: 2023-08-30End: 2028-02-28Updated: 2026-04-30

Phase 2

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
CompletedNCT02423863
Oncovir, Inc.Head and Neck Cancer, Melanoma, Non-Melanoma Skin Cancers +1
Start: 2015-03-31End: 2020-08-31Updated: 2020-12-17
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
CompletedNCT02873819
Gliknik Inc.Squamous Cell Carcinoma of the Oral Cavity
Start: 2017-03-30End: 2021-05-25Updated: 2022-03-08

Related Papers

A universal CD4 epitope enhances cytotoxic T-cell priming and memory in glioblastoma peptide vaccination 2257077
The Journal of Immunology2026-07-28
Abstract 6477: Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial
Cancer Research2026-04-03
Abstract CT057: Evaluation of tumor associated P30-peptide antigen (ETAPA): Safety and immunogenicity in a phase 1b trial in glioblastoma
Cancer Research2025-04-25
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Journal for ImmunoTherapy of Cancer2019-05-02125 citations
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Clinical Cancer Research2018-06-27126 citations
A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.
Journal of Clinical Oncology2017-05-2012 citations